LOX and breast cancer: Hypoxic tumors, along with HIF1 activation (e.g., breast cancer and head and neck cancer) are the main source of LOX, which is released systemically and disrupts ECM homeostasis in the pre-metastatic lung or bone (167) by crosslinking ECM molecules and primarily collagen.